Tom graduated University of Brighton with a BA (Hons) degree in Broadcast Journalism, leaving as the valedictorian of the class of 2015. His final year projects and dissertation were nominated for, and won, several awards, whilst he was also the Editor-in-Chief of the university’s news site during his time at Brighton. After previously writing for a property magazine, Tom joined the Proactive team in January 2016.
“We believe our unique approach to develop immuno-stimulating STAT3 inhibitors just took a major step forward”
Catabasis’ edasalonexent tablet helped to preserve muscle function and sustained “disease-modifying effects” in boys with DMD, while no side effects were observed
The UK pharma is once again back in court as it looks to prevent generic competition for its Suboxone herion addiction treatment, Indivior’s cash cow
GSK’s one pill, once daily treatment was approved back in November, while Gilead’s drug got the green light from the US FDA on Wednesday
Earlier this week, Moleculin said it had made a “major breakthrough” with its WP1732 candidate in preclinical testing
Evoke is to file a new drug application with the FDA in the second quarter of 2018, but it will only ask regulators to approve Gimoti for use in women
Technion is widely recognized as one of the global leaders in medical cannabis research
The two companies think they can improve ISS’s high pressure optical cell system by combining it with PBIO’s automated pressure generators
Of course if you’ve already done so, this article probably doesn’t apply to you…
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
As I venture into the world of equity trading, here’s the background to my story and where I’m at now